Direkt zum Inhalt
Merck

350R-2

Sigma-Aldrich

FOXP1 (EP137) Rabbit Monoclonal Primary Antibody

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352203

Biologische Quelle

rabbit

Qualitätsniveau

100
500

Konjugat

unconjugated

Antikörperform

culture supernatant

Antikörper-Produkttyp

primary antibodies

Klon

EP137, monoclonal

Beschreibung

For In Vitro Diagnostic Use in Select Regions

Form

buffered aqueous solution

Speziesreaktivität

human

Verpackung

vial of 0.1 mL concentrate (350R-24)
vial of 0.1 mL concentrate Research Use Only (350R-24-RUO)
vial of 0.5 mL concentrate (350R-25)
vial of 1.0 mL concentrate (350R-26)
vial of 1.0 mL concentrate Research Use Only (350R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (350R-27-RUO)
vial of 1.0 mL pre-dilute ready-to-use (350R-27)
vial of 7.0 mL pre-dilute ready-to-use (350R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (350R-28-RUO)

Hersteller/Markenname

Cell Marque

Methode(n)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)

Isotyp

IgG

Kontrolle

lymph node, tonsil

Versandbedingung

wet ice

Lagertemp.

2-8°C

Visualisierung

nuclear

Angaben zum Gen

human ... FOXP1(27086)

Allgemeine Beschreibung

Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique. Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies. Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform, using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

Qualität


IVD

IVD

IVD

RUO

Verlinkung

FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physikalische Form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Angaben zur Herstellung

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Sonstige Hinweise

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Rechtliche Hinweise

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

A A Alizadeh et al.
Nature, 403(6769), 503-511 (2000-02-17)
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in
J J F Muris et al.
The Journal of pathology, 208(5), 714-723 (2006-01-10)
Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable. Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis-regulating proteins Bcl-2 and XIAP have been found
Lluís Colomo et al.
Blood, 101(1), 78-84 (2002-10-24)
To analyze the relationship between immunophenotyping profile and main clinicopathological features and outcome in diffuse large B-cell lymphoma (DLBCL), we studied 128 patients (59 men, 69 women; median age 65 years) consecutively diagnosed with de novo DLBCL in a single
William W L Choi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5494-5502 (2009-08-27)
Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies
Christine P Hans et al.
Blood, 103(1), 275-282 (2003-09-25)
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.